Catalyst Wire Dossier Catalyst Wire Dossier

FYB201

ranibizumab biosimilar · Bioeq GmbH
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for FYB201, covering 2021-09-30 to 2021-09-30. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration [Phase 3]

See pricing